{"title":"播散性结节外大 B 细胞淋巴瘤（包括血管内大 B 细胞淋巴瘤）的前瞻性治疗研究。","authors":"Tomoyuki Sakai, Yusuke Ueda, Hiroto Yanagisawa, Kotaro Arita, Haruka Iwao, Kazunori Yamada, Shuichi Mizuta, Hiroshi Kawabata, Toshihiro Fukushima, Katsunori Tai, Shinji Kishi, Koji Morinaga, Jun Murakami, Hiroyuki Takamatsu, Yasushi Terasaki, Nobuyuki Yoshio, Yukio Kondo, Hirokazu Okumura, Sadaya Matano, Masaki Yamaguchi, Hiroshi Tsutani, Yasufumi Masaki","doi":"10.35772/ghm.2024.01021","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 4","pages":"277-281"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350362/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.\",\"authors\":\"Tomoyuki Sakai, Yusuke Ueda, Hiroto Yanagisawa, Kotaro Arita, Haruka Iwao, Kazunori Yamada, Shuichi Mizuta, Hiroshi Kawabata, Toshihiro Fukushima, Katsunori Tai, Shinji Kishi, Koji Morinaga, Jun Murakami, Hiroyuki Takamatsu, Yasushi Terasaki, Nobuyuki Yoshio, Yukio Kondo, Hirokazu Okumura, Sadaya Matano, Masaki Yamaguchi, Hiroshi Tsutani, Yasufumi Masaki\",\"doi\":\"10.35772/ghm.2024.01021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.</p>\",\"PeriodicalId\":12556,\"journal\":{\"name\":\"Global health & medicine\",\"volume\":\"6 4\",\"pages\":\"277-281\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350362/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global health & medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35772/ghm.2024.01021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health & medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35772/ghm.2024.01021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.
This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
